References: 1. Centers for Disease Control and Prevention. Basic information about ovarian cancer. Updated June 14, 2023. Accessed October 24, 2023. https://www.cdc.gov/cancer/ovarian/basic_info/index.htm 2. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25(19):2811-2818. 3. U.S. National Library of Medicine. IMGN853 with carboplatin in second-line treatment of FRα expressing, platinum-sensitive epithelial ovarian cancer. Updated May 17, 2023. Accessed October 24, 2023. https://clinicaltrials.gov/study/NCT05456685 4. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66(8):4426-4433. 5. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214-3221. 6. Altwerger G, Bonazzoli E, Bellone S, et al. In vitro and in vivo activity of IMGN853, an antibody–drug conjugate targeting folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers. Mol Cancer Ther. 2018;17(5):1003-1011.
Study 420 imgn853 失败
版权声明：本文内容由互联网用户自发贡献，该文观点仅代表作者本人。本站仅提供信息存储空间服务，不拥有所有权，不承担相关法律责任。如发现本站有涉嫌抄袭侵权/违法违规的内容， 请发送邮件至lizi9903@foxmail.com举报，一经查实，本站将立刻删除。